Skip to content

The efficacy and safety of strong sputum cream (smelting) for the treatment of acute tracheal-bronchitis cough (dryness and lung injury). Randomized, double-blind, double-simulated, positive drug parallel control, multi-center, Chinese medicine variety protection clinical trial

The efficacy and safety of strong sputum cream (smelting) for the treatment of acute tracheal-bronchitis cough (dryness and lung injury). Randomized, double-blind, double-simulated, positive drug parallel control, multi-center, Chinese medicine variety protection clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019748
Enrollment
Unknown
Registered
2018-11-26
Start date
2018-12-10
Completion date
Unknown
Last updated
2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute tracheal-bronchitis cough

Interventions

Group 1:Oral strong sputum cream (nectar) 20g/time, three times a day
Group 2:Oral Jizhi Tangjiang 20ml/time, three times a day

Sponsors

Beijing Chinese Medicine Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) It is an acute tracheal-bronchitis and its caused cough. The time from the start of coughing to the present visit does not exceed 2 weeks; (2) Daytime cough symptom score = 2 points or nocturnal cough symptom score = 2 points; (3) TCM syndrome differentiation is a dry evil and lung injury syndrome; (4) Aged 18 to 65 years old; (5) Voluntarily participate in clinical trials and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) diagnosed as pulmonary tuberculosis, bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, pneumonia, lung cancer and other lung diseases with cough symptoms; (2) The maximum body temperature exceeds 37.5 °C within 72 hours or other cough and phlegm drugs have been taken; (3) A large amount of sputum, which is mucinous or mucopurulent sputum, or bloody sputum; (4) The blood routine white blood cell count and the absolute value of neutrophils are greater than the upper limit of the reference range; (5) athletes; (6) Those with severe constipation or those with a history of intestinal obstruction in the past six months; (7) Patients with diabetes or glycated hemoglobin exceeding the reference range; (8) Any one of liver function ALT and AST exceeds the upper limit of reference value by 1.5 times, or TBil and Scr exceed the upper limit of reference value; (9) Patients with malignant tumors with primary diseases such as severe heart, lung, brain, liver, kidney and hematopoietic system; (10) those who are allergic or allergic to research drugs; (11) Fertility planners, pregnant or lactating women in the last 40 days; (12) Psychiatric patients, alcohol abusers and others who cannot cooperate with the completion of the study; (13) Those who participate in or are participating in other drug clinical trials within 3 months; (14) According to the judgment of the researcher, it is not appropriate to participate in this research.

Design outcomes

Primary

MeasureTime frame
Cough symptom score;Cough VAS score;TCM syndrome score;

Countries

China

Contacts

Public ContactYuguang Wang

Beijing Chinese Medicine Hospital affiliated to Capital Medical University

wygzhyiaids@126.com+86 010-52176034

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026